Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Narcolepsy01:07

Narcolepsy

422
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
422
Sleep-Wake Cycles01:24

Sleep-Wake Cycles

2.6K
Sleep is an essential physiological process vital to maintaining overall well-being. The reticular activating system (RAS), a network of neurons in the brainstem, regulates wakefulness and sleep. While it may seem passive, sleep consists of distinct cycles, each with its unique characteristics and functions. Two key sleep phases are non-rapid eye movement (NREM) and  rapid eye movement (REM).
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
2.6K
Management of Insomnia01:19

Management of Insomnia

450
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
450
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

406
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
406
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

441
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
441

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antibodies against influenza A/H1N1pdm2009 and B/Victoria strains but not A/H3N2 are increased in recent onset type 1 narcolepsy versus matched controls.

medRxiv : the preprint server for health sciences·2026
Same author

Protocol for the DREAMER study: Design and methodological framework of a multicenter trial-ready cohort of individuals with isolated REM sleep without atonia.

PloS one·2026
Same author

To diagnose Narcolepsy type 1 after a negative Multiple Sleep Latency Test: the contribution of systematic hypocretin measurement.

Sleep·2026
Same author

The Italian registry for narcolepsy and central disorders of hypersomnolence (ReN&IS): Baseline clinical and diagnostic findings.

Sleep medicine·2026
Same author

Sensor-Based Assessment of Morning Prospective Memory in Narcolepsy Type 1: Evidence from Children and Adult Cohorts.

Sensors (Basel, Switzerland)·2026
Same author

Burden among participants with central disorders of hypersomnolence in six European countries.

Sleep medicine·2026
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

Related Experiment Video

Updated: Dec 29, 2025

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
05:59

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

2.9K

Immunotherapy in Narcolepsy.

Maria Pia Giannoccaro1,2, Giombattista Sallemi1, Rocco Liguori1,2

  • 1Department of Biomedical and Neuromotor Sciences, University of Bologna, Ospedale Bellaria, Padiglione G, piano 1, Via Altura 3, 40139 Bologna, Italy.

Current Treatment Options in Neurology
|January 31, 2020
PubMed
Summary
This summary is machine-generated.

Immunotherapy shows limited evidence for treating narcolepsy type 1 (NT1). Current studies lack robust data, necessitating further randomized trials to confirm its effectiveness in managing this autoimmune sleep disorder.

Keywords:
AutoimmunityCorticosteroidImmunotherapyIntravenous immunoglobulinMonoclonal antibodiesNarcolepsy type 1

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.7K
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

21.8K

Related Experiment Videos

Last Updated: Dec 29, 2025

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
05:59

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

2.9K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.7K
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

21.8K

Area of Science:

  • Neurology
  • Immunology
  • Sleep Medicine

Background:

  • Narcolepsy type 1 (NT1) is a chronic autoimmune sleep disorder caused by hypocretin neuron loss.
  • Current treatments for NT1 are symptomatic, with no available cure.
  • Immunotherapy is being explored as a potential future treatment for NT1.

Purpose of the Study:

  • To review the rationale for immunotherapy in narcolepsy.
  • To evaluate current evidence on immunotherapy's effects in NT1.
  • To discuss outcome measures and future research directions for NT1 immunotherapy.

Main Methods:

  • Review of case reports and small, uncontrolled case series on various immunotherapies (IVIg, corticosteroids, plasmapheresis, monoclonal antibodies).
  • Analysis of reported symptom improvements and contrasting findings.
  • Assessment of outcome measures and their standardization, particularly in pediatric populations.

Main Results:

  • Initial reports suggested symptom improvement with immunotherapy, especially when initiated early in NT1.
  • Subsequent observations have not consistently confirmed these benefits.
  • Contrasting results may be due to treatment timing, placebo effects, or natural disease progression.
  • Lack of standardized outcome measures hinders definitive conclusions, especially in pediatric NT1.

Conclusions:

  • There is insufficient evidence to support the use of immunotherapy for narcolepsy type 1.
  • Randomized, controlled studies with clear endpoints and validated outcome measures are essential.
  • Further research is required to determine the true efficacy of immunotherapy in NT1.